Amgen (AMGN) Equity Ratio (2009 - 2026)
Amgen's quarterly Equity Ratio came in at 0.1 in Q1 2026, up 43.04% year-on-year from 0.07 in Q1 2025, and up 3.94% quarter-over-quarter from 0.1 in Q4 2025.
Amgen has reported Equity Ratio for 18 years, with the latest figure at 0.1 in Q1 2026.
- For the quarter ending Q1 2026, Equity Ratio rose 43.04% year-over-year to 0.1; the trailing twelve-month figure through Mar 2026 stood at 0.1 (up 43.04% YoY), and the FY2025 full-year result was 0.1, up 49.36% from the prior year.
- Equity Ratio for Q1 2026 stood at 0.1, up from 0.1 in the prior quarter.
- The five-year high for Equity Ratio was 0.11 in Q3 2025, with the low at 0.02 in Q1 2022.
- Average Equity Ratio over 5 years is 0.07, with a median of 0.07 recorded in 2024.
- Year-over-year, Equity Ratio sank 89.63% in 2022 and jumped 289.55% in 2023.
- Tracing AMGN's Equity Ratio over 5 years: stood at 0.06 in 2022, then gained by 14.1% to 0.06 in 2023, then fell by 0.24% to 0.06 in 2024, then soared by 49.36% to 0.1 in 2025, then gained by 3.94% to 0.1 in 2026.
- The last three Equity Ratio figures came in at 0.1 (Q1 2026), 0.1 (Q4 2025), and 0.11 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 0.27 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 0.40 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | -0.05 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 0.36 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 0.10 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 0.42 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.43 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 0.23 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | 0.27 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.10 |
| Dec 31, 2025 | 0.10 |
| Sep 30, 2025 | 0.11 |
| Jun 30, 2025 | 0.08 |
| Mar 31, 2025 | 0.07 |
| Dec 31, 2024 | 0.06 |
| Sep 30, 2024 | 0.08 |
| Jun 30, 2024 | 0.07 |
| Mar 31, 2024 | 0.05 |
| Dec 31, 2023 | 0.06 |
| Sep 30, 2023 | 0.08 |
| Jun 30, 2023 | 0.08 |
| Mar 31, 2023 | 0.06 |
| Dec 31, 2022 | 0.06 |
| Sep 30, 2022 | 0.06 |
| Jun 30, 2022 | 0.04 |
| Mar 31, 2022 | 0.02 |
| Dec 31, 2021 | 0.11 |
| Sep 30, 2021 | 0.13 |
| Jun 30, 2021 | 0.14 |
| Mar 31, 2021 | 0.15 |
| Dec 31, 2020 | 0.15 |
| Sep 30, 2020 | 0.17 |
| Jun 30, 2020 | 0.16 |
| Mar 31, 2020 | 0.15 |
| Dec 31, 2019 | 0.16 |
| Sep 30, 2019 | 0.18 |
| Jun 30, 2019 | 0.18 |
| Mar 31, 2019 | 0.17 |
| Dec 31, 2018 | 0.19 |
| Sep 30, 2018 | 0.21 |
| Jun 30, 2018 | 0.22 |
| Mar 31, 2018 | 0.22 |
| Dec 31, 2017 | 0.32 |
| Sep 30, 2017 | 0.40 |
| Jun 30, 2017 | 0.00 |
| Mar 31, 2017 | 0.00 |
| Dec 31, 2016 | 0.38 |
| Sep 30, 2016 | 0.39 |
| Jun 30, 2016 | 0.00 |
| Mar 31, 2016 | 0.00 |
| Dec 31, 2015 | 0.39 |
| Sep 30, 2015 | 0.39 |
| Jun 30, 2015 | 0.39 |
| Mar 31, 2015 | 0.38 |
| Dec 31, 2014 | 0.37 |
| Sep 30, 2014 | 0.36 |
| Jun 30, 2014 | 0.35 |
| Mar 31, 2014 | 0.34 |
| Dec 31, 2013 | 0.33 |
| Sep 30, 2013 | 0.38 |
| Jun 30, 2013 | 0.39 |
| Mar 31, 2013 | 0.38 |
| Dec 31, 2012 | 0.35 |
| Sep 30, 2012 | 0.36 |
| Dec 31, 2011 | 0.39 |
| Mar 31, 2010 | 0.55 |
| Dec 31, 2009 | 0.57 |
| Sep 30, 2009 | 0.56 |
| Jun 30, 2009 | 0.55 |